Safety and efficacy of a non-steroidal anti-androgen, based on results of a post marketing surveillance of nilutamide-Reference-Cited by-同舟云学术

Safety and efficacy of a non-steroidal anti-androgen, based on results of a post marketing surveillance of nilutamide

Published:2001-06 Issue:2 Volume:4 Page:112-117
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Schasfoort EMC,van de Beek C,Newling DWW

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/4500516.pdf

Reference18 articles.

1. Schröder FH et al. European randomised study of screening for prostate cancer, the Rotterdam pilot studies. Int J Cancer 1996 65 145–151.

2. Huggins C, Hodge C. Studies on prostatic cancer. The effects of castration, oestrogen or androgen therapy on SAP in metastic cancer of the prostate. Cancer Res 1941 1 293–297.

3. Borgmann V et al Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach? Lancet 1982 15 1097–1099.

4. Huggins S. Bilateral adrenalectomy in prostatic cancer. Ann Surg 1945 122 1031–1037.

5. Harris MG, Coleman SG, Faulds D, Chrisp P. Nilutamide a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. Drugs & Aging 1993 3 9–25.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions;International Journal of Molecular Sciences;2020-12-14

2. Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope;Cancers;2019-12-23

3. Second-Line Hormonal for Castrate-Resistant Prostate Cancer;Prostate Cancer;2016

4. Antiandrogen Monotherapy in the Treatment of Prostate Cancer;Prostate Cancer;2016

5. Monotherapy with Antiandrogens in the Treatment of Prostate Cancer;Prostate Cancer;2003